There were essentially 2 ways things could have gone in the past 2 years. The way they did and the way they did with Nuvaring being approved in 2019. I don't think everyone would have been so critical if Nuvaring had been approved in 2019. The generics issue would have still been there but Nuvaring would have smoothed things out a lot. I don't think you can blame Mayne for Nuvaring. Mithra got it approved in several other markets and the FDA knock back really seems to have been a left field thing. In 2019, on the balance of probabilities of approval or not approval, the odds would have been on approval. It just didn't happen. But back to the future. If gNuvaring is approved shortly, Mayne will have had 2 big guns products approved in 6 months. Let's see how it goes but I'm confident.
- Forums
- ASX - By Stock
- MYX
- Ann: Change of Director's Interest Notice
Ann: Change of Director's Interest Notice, page-14
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.72 |
Change
0.040(0.85%) |
Mkt cap ! $401.5M |
Open | High | Low | Value | Volume |
$4.68 | $4.77 | $4.68 | $560.3K | 118.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 107 | $4.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.75 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 107 | 4.720 |
1 | 108 | 4.710 |
3 | 2594 | 4.700 |
2 | 594 | 4.690 |
2 | 594 | 4.680 |
Price($) | Vol. | No. |
---|---|---|
4.750 | 1500 | 1 |
4.760 | 648 | 1 |
4.770 | 648 | 1 |
4.780 | 756 | 2 |
4.790 | 2511 | 2 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online